Figure 3

Kaplan–Meier estimates of the overall survival of CGGA patients using the six-pseudogene signature. The Kaplan–Meier plots were used to visualize the survival probabilities for the low-risk versus high-risk group of CGGApatients determined on the basis of the median risk score. (A) Kaplan–Meier curves for CGGA training-set patients (n = 183); (B) Kaplan–Meier curves for REMBRANDT patients (n = 350); The tick marks on the Kaplan–Meier curves represent the censored subjects. The differences between the two curves were determined by the two-sided log-rank test. The number of patients at risk was listed below the survival curves.